A multicentre, randomised study of photodynamic therapy (PDT) with Metvix [methyl-aminolevulinate] 160 mg/g cream in immuno-compromised patients with non-melanoma skin cancer.

Trial Profile

A multicentre, randomised study of photodynamic therapy (PDT) with Metvix [methyl-aminolevulinate] 160 mg/g cream in immuno-compromised patients with non-melanoma skin cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2010

At a glance

  • Drugs Methyl aminolevulinate (Primary)
  • Indications Actinic keratosis; Basal cell cancer; Skin cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors PhotoCure
  • Most Recent Events

    • 01 Dec 2008 New reference added. Results published in Transplantation 86: 423-429, No. 3, 15 Aug 2008.
    • 21 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top